Cures 2.0 May Get Fast Tracked Due To COVID-19
Follow-up bill to the 21st Century Cures Act looks to be more focused on reimbursement and delivery than the 2016 law, which centered on speeding drug development and approval. The bill's architects are working to get some of their provisions, including those around antibiotics, attached to the next COVID-19 relief legislation.
You may also be interested in...
The coronavirus pandemic highlights the work that is still needed on real-world evidence, agency's principal deputy commissioner says.
After two years of significant growth in non-user fee funds, House appropriators offer FDA a more modest increase for FY 2021.
Richard Pazdur wants the oncology community to take a fresh look at US FDA’s expedited review programs. One big question: should there be fewer of them?